{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:27:53Z","timestamp":1763036873652},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["L'Enc\u00e9phale"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.encep.2014.12.001","type":"journal-article","created":{"date-parts":[[2015,1,28]],"date-time":"2015-01-28T22:34:36Z","timestamp":1422484476000},"page":"39-46","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Quels crit\u00e8res pour un traitement antipsychotique id\u00e9al\u00a0?"],"prefix":"10.1016","volume":"41","author":[{"given":"R.","family":"Bordet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.encep.2014.12.001_bib0005","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","article-title":"Schizophrenia","volume":"374","author":"Van Os","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.encep.2014.12.001_bib0010","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.nurt.2008.10.020","article-title":"Building better antipsychotic: receptor targets for their multiple symptom dimensions of schizophrenia","volume":"6","author":"Kim","year":"2009","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.encep.2014.12.001_bib0015","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/ern.09.143","article-title":"Effect of second-generation antipsychotics on cognition: current issues and future challenges","volume":"10","author":"Hill","year":"2010","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.encep.2014.12.001_bib0020","series-title":"Les antipsychotiques","first-page":"7","article-title":"Pharmacologie des antipsychotiques: acquis, diversit\u00e9 et perspectives","author":"Bordet","year":"2014"},{"key":"10.1016\/j.encep.2014.12.001_bib0025","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1124\/pr.107.00107","article-title":"Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection","volume":"60","author":"Lieberman","year":"2008","journal-title":"Pharmacol Rev"},{"issue":"suppl 18","key":"10.1016\/j.encep.2014.12.001_bib0030","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1017\/S1092852900025906","article-title":"Neuroprotection: a new strategy in the treatment of schizophrenia. Neurobiological basis of neurodegeneration and neuroprotection","volume":"12","author":"Lieberman","year":"2007","journal-title":"CNS Spectr"},{"issue":"5suppl","key":"10.1016\/j.encep.2014.12.001_bib0035","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/0269881111424929","article-title":"Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons","volume":"26","author":"Haddad","year":"2012","journal-title":"J Psychopharmacol"},{"issue":"2","key":"10.1016\/j.encep.2014.12.001_bib0040","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.encep.2014.12.001_bib0045","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/JCP.0b013e3182214aad","article-title":"Dopamine D2\u00a0receptor occupancy and clinical effects: a systematic review and pooled analysis","volume":"31","author":"Uchida","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.encep.2014.12.001_bib0050","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3371\/CSRP.4.1.5","article-title":"Dopamine D2\u00a0receptors as treatment targets in schizophrenia","volume":"4","author":"Seeman","year":"2010","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"10.1016\/j.encep.2014.12.001_bib0055","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1586\/ern.10.191","article-title":"Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment","volume":"11","author":"Remington","year":"2011","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.encep.2014.12.001_bib0060","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.pnpbp.2003.09.004","article-title":"Half a century of antipsychotics and still a central role for dopamine D2\u00a0receptors","volume":"27","author":"Kapur","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.encep.2014.12.001_bib0065","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.coph.2011.02.007","article-title":"The role of serotonin receptors in the action of atypical antipsychotic drugs","volume":"11","author":"Meltzer","year":"2011","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.encep.2014.12.001_bib0070","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0079-6123(08)00909-6","article-title":"In vivo actions of atypical antipsychotic drug on serotoninergic and dopaminergic systems","volume":"172","author":"Meltzer","year":"2008","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.encep.2014.12.001_bib0075","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/npp.2011.181","article-title":"From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment","volume":"37","author":"Moqhaddam","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.encep.2014.12.001_bib0080","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/sj.mp.4002062","article-title":"The pipeline and future of drug development in schizophrenia","volume":"12","author":"Gray","year":"2007","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.encep.2014.12.001_bib0085","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2174\/187152707781387323","article-title":"Novel targets for drugs in schizophrenia","volume":"6","author":"Stone","year":"2007","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.encep.2014.12.001_bib0090","doi-asserted-by":"crossref","first-page":"359","DOI":"10.31887\/DCNS.2010.12.3\/jcoyle","article-title":"Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia","volume":"12","author":"Coyle","year":"2010","journal-title":"Dialogues Clin Neurosci"},{"key":"10.1016\/j.encep.2014.12.001_bib0095","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.tips.2010.05.004","article-title":"Signaling pathways in schizophrenia: emerging targets and therapeutic strategies","volume":"31","author":"Karam","year":"2010","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.encep.2014.12.001_bib0100","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/7854_2010_47","article-title":"Antipsychotic drug development","volume":"4","author":"Kim","year":"2010","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1016\/j.encep.2014.12.001_bib0105","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1517\/13543784.2011.601738","article-title":"Serotonin 2A receptor antagonists for treatment of schizophrenia","volume":"20","author":"Ebdrup","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.encep.2014.12.001_bib0110","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1358\/dnp.2010.23.4.1416977","article-title":"The antipsychotic potential of muscarinic allosteric modulation","volume":"23","author":"Bridges","year":"2010","journal-title":"Drug News Perspect"},{"key":"10.1016\/j.encep.2014.12.001_bib0115","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2174\/157015908785777247","article-title":"Role of the central cholinergic system in the therapeutics of schizophrenia","volume":"6","author":"Terry","year":"2008","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.encep.2014.12.001_bib0120","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2174\/138161211795049561","article-title":"\u03b17\u00a0nicotinic acetylcholine receptor as a potential therapeutic target for schizophrenia","volume":"17","author":"Ishikawa","year":"2011","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.encep.2014.12.001_bib0125","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.molmed.2011.08.004","article-title":"Targeting glutamate synapses in schizophrenia","volume":"17","author":"Field","year":"2011","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.encep.2014.12.001_bib0130","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/070674371005500302","article-title":"Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making","volume":"55","author":"Foussias","year":"2010","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.encep.2014.12.001_bib0135","first-page":"649","article-title":"The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians","volume":"23","author":"Naber","year":"2009","journal-title":"CNS Drugs"},{"issue":"11","key":"10.1016\/j.encep.2014.12.001_bib0140","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1517\/14656566.2011.626767","article-title":"A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia","volume":"13","author":"Citrome","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.encep.2014.12.001_bib0145","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1146\/annurev.med.58.060904.084114","article-title":"Schizophrenia: new pathological insights and therapies","volume":"58","author":"Jarskog","year":"2007","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.encep.2014.12.001_bib0150","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/7854_2010_39","article-title":"Pharmacological strategies for enhancing cognition in schizophrenia","volume":"4","author":"Barch","year":"2010","journal-title":"Curr Top Behav Neurosci"},{"issue":"suppl2","key":"10.1016\/j.encep.2014.12.001_bib0155","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s00406-011-0242-2","article-title":"Schizophrenia a disorder of connectivity","volume":"261","author":"Schmitt","year":"2011","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"2","key":"10.1016\/j.encep.2014.12.001_bib0160","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11126-011-9189-8","article-title":"Is there evidence for late cognitive decline in chronic schizophrenia?","volume":"83","author":"Shah","year":"2012","journal-title":"Psychiatr Q"},{"key":"10.1016\/j.encep.2014.12.001_bib0165","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2165\/11595380-000000000-00000","article-title":"Pharmacogenetics of response to antipsychotics in patients with schizophrenia","volume":"25","author":"Arranz","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.encep.2014.12.001_bib0170","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1440-1819.2010.02168.x","article-title":"Pharmacogenomics of antipsychotics efficacy for schizophrenia","volume":"65","author":"Cacabelos","year":"2011","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.encep.2014.12.001_bib0175","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Mol Psychiatry"}],"container-title":["L'Enc\u00e9phale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700614002826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700614002826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T21:55:13Z","timestamp":1651096513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0013700614002826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0013700614002826"],"URL":"https:\/\/doi.org\/10.1016\/j.encep.2014.12.001","relation":{},"ISSN":["0013-7006"],"issn-type":[{"value":"0013-7006","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quels crit\u00e8res pour un traitement antipsychotique id\u00e9al\u00a0?","name":"articletitle","label":"Article Title"},{"value":"L'Enc\u00e9phale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.encep.2014.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 L\u2019Enc\u00e9phale, Paris. Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}